IP Library Granted Patent US 7,244,577
Granted Patent B2
US 7,244,577 · App. 10/331,907 · Granted Jul 17, 2007

Method of screening for modulator of LRP5 activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,244,577
App. No.
10/331,907
Granted
Jul 17, 2007
Kind
B2
Abstract

A novel receptor, “LDL-receptor-related protein-5” (“LRP-5”), is provided, along with encoding nucleic acid. The gene is associated with type 1 diabetes (insulin dependent diabetes mellitus), and experimental evidence provides indication that it is the IDDM susceptibility gene IDDM4. In various aspects the invention provides nucleic acid, including coding sequences, oligonucleotide primers and probes, polypeptides, pharmaceutical compositions, methods of diagnosis or prognosis, and other methods relating to and based on the gene, including methods of treatment of diseases in which the gene may be implicated, including autoimmune diseases, such as glomerulonephritis, diseases and disorders involving disruption of endocytosis and/or antigen presentation, diseases and disorders involving cytokine clearance and/or inflammation, viral infection, elevation of free fatty acids or hypercholesterolemia, osteoporosis, Alzheimer's disease, and diabetes.

Claims (5)

1. A method of screening for a modulator of LDL-receptor related protein-5 (LRP5) activity wherein the activity is selected from the group consisting of (1) LRP5 polypeptide binding and taking up LDL and (2) LRP5 polypeptide modulation of triglyceride and lipoprotein levels, which comprises:

(a) providing a recombinant LRP5 polypeptide comprising the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:4;

(b) contacting the LRP5 polypeptide with a test substance

(c) testing the activity of the LRP5 polypeptide with the test substance; and,

(d) comparing the activity of the LRP5 polypeptide with the test substance to the activity of the LRP5 polypeptide without the test substance, wherein a difference in the activity indicates that the test substance modulates LRP5 activity.

Assignments (4)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 29, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023861/0910 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2005
From: THE WELLCOME TRUST LIMITED AS TRUSTEE FOR THE WELLCOME TRUST
To: MERCK & CO., INC.
Reel/Frame 015629/0718 →